RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.040
-0.120 (-10.34%)
Nov 13, 2026, 4:00 PM EST - Market closed

RenovoRx Statistics

Total Valuation

RenovoRx has a market cap or net worth of $50.18 million. The enterprise value is $40.13 million.

Market Cap50.18M
Enterprise Value 40.13M

Important Dates

The last earnings date was Thursday, November 5, 2026, after market close.

Earnings Date Nov 5, 2026
Ex-Dividend Date n/a

Share Statistics

RenovoRx has 48.25 million shares outstanding. The number of shares has increased by 31.21% in one year.

Current Share Class 48.25M
Shares Outstanding 48.25M
Shares Change (YoY) +31.21%
Shares Change (QoQ) +1.90%
Owned by Insiders (%) 3.23%
Owned by Institutions (%) 15.48%
Float 42.43M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 18.08
Forward PS 5.97
PB Ratio 5.40
P/TBV Ratio 5.41
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 14.46
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 5.65, with a Debt / Equity ratio of 0.04.

Current Ratio 5.65
Quick Ratio 5.27
Debt / Equity 0.04
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -149.98% and return on invested capital (ROIC) is -90.33%.

Return on Equity (ROE) -149.98%
Return on Assets (ROA) -68.60%
Return on Invested Capital (ROIC) -90.33%
Return on Capital Employed (ROCE) -125.42%
Weighted Average Cost of Capital (WACC) 10.61%
Revenue Per Employee $163,294
Profits Per Employee -$765,882
Employee Count17
Asset Turnover 0.23
Inventory Turnover 1.45

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +4.00% in the last 52 weeks. The beta is 1.17, so RenovoRx's price volatility has been higher than the market average.

Beta (5Y) 1.17
52-Week Price Change +4.00%
50-Day Moving Average 1.45
200-Day Moving Average 1.11
Relative Strength Index (RSI) 34.83
Average Volume (20 Days) 425,653

Short Selling Information

The latest short interest is 997,993, so 2.07% of the outstanding shares have been sold short.

Short Interest 997,993
Short Previous Month 864,570
Short % of Shares Out 2.07%
Short % of Float 2.35%
Short Ratio (days to cover) 2.43

Income Statement

In the last 12 months, RenovoRx had revenue of $2.78 million and -$13.02 million in losses. Loss per share was -$0.31.

Revenue2.78M
Gross Profit 2.33M
Operating Income -12.98M
Pretax Income -13.02M
Net Income -13.02M
EBITDA -12.96M
EBIT -12.98M
Loss Per Share -$0.31
Full Income Statement

Balance Sheet

The company has $10.40 million in cash and $358,000 in debt, with a net cash position of $10.05 million or $0.21 per share.

Cash & Cash Equivalents 10.40M
Total Debt 358,000
Net Cash 10.05M
Net Cash Per Share $0.21
Equity (Book Value) 9.28M
Book Value Per Share 0.19
Working Capital 9.72M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$12.14 million and capital expenditures -$90,000, giving a free cash flow of -$12.23 million.

Operating Cash Flow -12.14M
Capital Expenditures -90,000
Depreciation & Amortization 12,000
Net Borrowing n/a
Free Cash Flow -12.23M
FCF Per Share -$0.25
Full Cash Flow Statement

Margins

Gross Margin 84.04%
Operating Margin -467.44%
Pretax Margin -469.02%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

RenovoRx does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -31.21%
Shareholder Yield -31.21%
Earnings Yield -29.41%
FCF Yield -24.36%

Analyst Forecast

The average price target for RenovoRx is $7.25, which is 597.12% higher than the current price. The consensus rating is "Strong Buy".

Price Target $7.25
Price Target Difference 597.12%
Analyst Consensus Strong Buy
Analyst Count 4
Revenue Growth Forecast (3Y) 210.23%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

RenovoRx has an Altman Z-Score of -2.01 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -2.01
Piotroski F-Score 3